559 related articles for article (PubMed ID: 35634292)
1. Autoimmunity and Cancer-Two Sides of the Same Coin.
Sakowska J; Arcimowicz Ł; Jankowiak M; Papak I; Markiewicz A; Dziubek K; Kurkowiak M; Kote S; Kaźmierczak-Siedlecka K; Połom K; Marek-Trzonkowska N; Trzonkowski P
Front Immunol; 2022; 13():793234. PubMed ID: 35634292
[TBL] [Abstract][Full Text] [Related]
2. Clinical and molecular impact of concurrent thyroid autoimmune disease and thyroid cancer: From the bench to bedside.
Dos Santos Valsecchi VA; Betoni FR; Ward LS; Cunha LL
Rev Endocr Metab Disord; 2024 Feb; 25(1):5-17. PubMed ID: 37889392
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
Kumar P; Bhattacharya P; Prabhakar BS
J Autoimmun; 2018 Dec; 95():77-99. PubMed ID: 30174217
[TBL] [Abstract][Full Text] [Related]
4. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
Fife BT; Bluestone JA
Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
[TBL] [Abstract][Full Text] [Related]
5. Is autoimmunity the Achilles' heel of cancer immunotherapy?
June CH; Warshauer JT; Bluestone JA
Nat Med; 2017 May; 23(5):540-547. PubMed ID: 28475571
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for cancer treatment.
Donátová K; Nováková E; Šupolíková M
Klin Onkol; 2022; 35(4):284-289. PubMed ID: 35989085
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again.
Bucktrout SL; Bluestone JA; Ramsdell F
Genome Med; 2018 Oct; 10(1):79. PubMed ID: 30376867
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Kumar P; Saini S; Prabhakar BS
Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
[TBL] [Abstract][Full Text] [Related]
9. Stimulatory and Inhibitory Co-signals in Autoimmunity.
Okazaki T; Okazaki IM
Adv Exp Med Biol; 2019; 1189():213-232. PubMed ID: 31758536
[TBL] [Abstract][Full Text] [Related]
10. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
11. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.
Pauken KE; Dougan M; Rose NR; Lichtman AH; Sharpe AH
Trends Immunol; 2019 Jun; 40(6):511-523. PubMed ID: 31053497
[TBL] [Abstract][Full Text] [Related]
12. [Not Available].
Senant M; Giusti D; Weiss L; Dragon-Durey MA
Bull Cancer; 2016 Nov; 103 Suppl 1():S175-S185. PubMed ID: 28057182
[TBL] [Abstract][Full Text] [Related]
13. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
[TBL] [Abstract][Full Text] [Related]
14. Unleashing the pathological imprinting of cancer in autoimmunity: Is ZEB1 the answer?
Rithvik A; Samarpita S; Rasool M
Life Sci; 2023 Nov; 332():122115. PubMed ID: 37739160
[TBL] [Abstract][Full Text] [Related]
15. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.
Guram K; Kim SS; Wu V; Sanders PD; Patel S; Schoenberger SP; Cohen EEW; Chen SY; Sharabi AB
Front Immunol; 2019; 10():491. PubMed ID: 30936880
[TBL] [Abstract][Full Text] [Related]
16. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
Dempke WCM; Fenchel K; Uciechowski P; Dale SP
Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
[TBL] [Abstract][Full Text] [Related]
17. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Phan GQ; Yang JC; Sherry RM; Hwu P; Topalian SL; Schwartzentruber DJ; Restifo NP; Haworth LR; Seipp CA; Freezer LJ; Morton KE; Mavroukakis SA; Duray PH; Steinberg SM; Allison JP; Davis TA; Rosenberg SA
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8372-7. PubMed ID: 12826605
[TBL] [Abstract][Full Text] [Related]
18. Learning from the nexus of autoimmunity and cancer.
Mangani D; Yang D; Anderson AC
Immunity; 2023 Feb; 56(2):256-271. PubMed ID: 36792572
[TBL] [Abstract][Full Text] [Related]
19. Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model.
Zhang B; Chikuma S; Hori S; Fagarasan S; Honjo T
Proc Natl Acad Sci U S A; 2016 Jul; 113(30):8490-5. PubMed ID: 27410049
[TBL] [Abstract][Full Text] [Related]
20. Coinhibitory Pathways in Immunotherapy for Cancer.
Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
